Literature DB >> 8168113

Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth.

C C Kappel1, M C Velez-Yanguas, S Hirschfeld, L J Helman.   

Abstract

Osteogenic sarcoma is the most common bone tumor of childhood and typically occurs during the adolescent growth spurt when growth hormone and insulin-like growth factor I (IGF-I) may be at their lifetime highest levels. Since IGF-I is involved in normal bone growth and differentiation, we have evaluated the possible role of IGF-I signaling in the growth of human osteogenic sarcoma cell lines. In this study, we demonstrate that in vitro survival of cells is dependent on exogenously supplied IGF-I. Furthermore, we show that these cells display functional IGF-I receptors on their surface and that in vitro growth is inhibited by blocking these receptors either by monoclonal antibodies or by antisense oligonucleotides. These data demonstrate that human osteogenic sarcoma cell lines are dependent on signaling through the IGF-I receptor for in vitro survival and proliferation. Furthermore, they suggest that modulation of the growth hormone/IGF-I axis may affect the growth of these tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168113

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 2.  Osteosarcoma and acromegaly: a case report and review of the literature.

Authors:  G A B Lima; E M S Gomes; R C Nunes; L Vieira Neto; A P A V Sieiro; E P Brabo; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

3.  Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

4.  Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study.

Authors:  Scott C Borinstein; Donald A Barkauskas; Mark Bernstein; Allen Goorin; Richard Gorlick; Mark Krailo; Cindy L Schwartz; Leonard H Wexler; Jeffrey A Toretsky
Journal:  Pediatr Blood Cancer       Date:  2013-10-31       Impact factor: 3.167

5.  Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model.

Authors:  Nino Rainusso; Tsz-Kwong Man; Ching C Lau; John Hicks; Jianhe J Shen; Alexander Yu; Lisa L Wang; Jeffrey M Rosen
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

6.  Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

7.  The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis.

Authors:  Peng Chen; Shao-jin Wang; Hong-bo Wang; Peng Ren; Xi-qian Wang; Wen-guang Liu; Wan-li Gu; Dong-qing Li; Ting-guo Zhang; Cheng-jun Zhou
Journal:  J Mol Histol       Date:  2011-11-01       Impact factor: 2.611

8.  The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).

Authors:  Maria A Pantaleo; Annalisa Astolfi; Margherita Nannini; Guido Biasco
Journal:  J Transl Med       Date:  2010-11-15       Impact factor: 5.531

9.  Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.

Authors:  Mandy Geryk-Hall; Dennis P M Hughes
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

10.  Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I.

Authors:  Sung-Hyeok Hong; Joseph Briggs; Rachel Newman; Karen Hoffman; Arnulfo Mendoza; Derek LeRoith; Lee Helman; Shoshana Yakar; Chand Khanna
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.